Zhixuan Li

1.8k citations
21 papers · 729 indexed · h-index 11
    • Cancer Genomics and Diagnostics 3
    • MicroRNA in disease regulation 2
    • Immune Cell Function and Interaction 3
    • Immune cells in cancer 3
    • Cancer Immunotherapy and Biomarkers 4
    • Pancreatic and Hepatic Oncology Research 3
    • Cancer Cells and Metastasis 2
    • Cholangiocarcinoma and Gallbladder Cancer Studies 2

Zhixuan Li

19 papers receiving 723 citations

Peers

Zhixuan Li
Comparison fields: 5 of 86
  • Cancer Research 303
  • Immunology 189
  • Oncology 198
  • Otorhinolaryngology 31
  • Hepatology 45
Replace Fangfang Duan with:
Fangfang Duan China
Azharuddin Sajid Syed Khaja Saudi Arabia
Hongyong Song China
Yaya Yu China
Songlin Peng China
Vassilios Atsaves United States
Esther Hermano Israel
Pengbo Deng China
Weina Li China
Zhixuan Li relative to Fangfang Duan China Fangfang Duan's profile →
Citations per field
00.5×4.1×
Fangfang Duan · 1×
Citations per year

Countries citing papers authored by Zhixuan Li

Since Specialization
Citations

This map shows the geographic impact of Zhixuan Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhixuan Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhixuan Li more than expected).

Fields of papers citing papers by Zhixuan Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhixuan Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhixuan Li. The network helps show where Zhixuan Li may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Zhixuan Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Zhixuan Li Line = papers co-authored together Zhixuan Li links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20250
2 20250
3 20245
4 202344
5 20236
6 202334
7 20228
8 20228
9 20221
10 202248
11 202122
12 202193
13 20213
14 20216
15 202027
16 202081
17 2019202
18 201983
19 201618
20 20132

About Zhixuan Li

Zhixuan Li is a scholar working on Structural Biology, Cancer Research and Immunology, having authored 21 papers that have together received 729 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (4 papers), Immune Cell Function and Interaction (3 papers), Pancreatic and Hepatic Oncology Research (3 papers), Immune cells in cancer (3 papers), Cancer Genomics and Diagnostics (3 papers), MicroRNA in disease regulation (2 papers), Cancer Cells and Metastasis (2 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (2 papers). The work is most often cited by research in Cancer Research (303 citations), Immunology (189 citations) and Oncology (198 citations). Zhixuan Li has collaborated with scholars based in China, United States and South Korea. Frequent co-authors include Lei Chen, Tong Wu, Bo Zheng, Rui Wu, Yanjing Zhu, Hongyang Wang, Shuai Yang, Guijuan Luo, Yang Ge and Siyun Shen. Their work appears in journals such as Cancer, Food Chemistry and Advanced Science.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026